北美的體外診斷市場預測:臨床化學檢驗·遺傳基因檢驗·血液檢驗·組織/細胞檢驗，免疫化學檢查·感染/免疫疾病檢驗·微生物學培養檢驗

北美的體外診斷市場預測:臨床化學檢驗·遺傳基因檢驗·血液檢驗·組織/細胞檢驗，免疫化學檢查·感染/免疫疾病檢驗·微生物學培養檢驗 是由出版商GlobalData在2012年01月所出版的。 這份英文市場調查報告書包含Pages: 439 價格從美金3500起跳。

簡介

本報告提供北美的體外診斷市場相關資料，市場整體及各國分析、各國總收益實績及預測資料、加上企業及流通管道佔有率資料、各開發平台產品分析、體外診斷市場相關法規、財務交易狀況、主要企業的簡介等資料彙整，為您概述為以下內容。

1. 目錄

• 1.1 表格一覽
• 1.2 圖表一覽

2. 簡介

• 2.1 關於本報告

3. 體外診斷 - 北美

• 3.1 體外診斷 多國間比較, USD 以實額為基礎, 實際成果及預測
• 3.2 體外診斷, 北美, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 3.3 體外診斷, 北美, 企業佔有率

4. 體外診斷 - 加拿大

• 4.1 體外診斷, 加拿大, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 4.2 體外診斷, 加拿大, 流通佔有率
• 4.3 體外診斷, 加拿大, 企業佔有率

5. 體外診斷 - 美國

• 5.1 體外診斷, 美國, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 5.2 體外診斷, 美國 流通佔有率
• 5.3 體外診斷, 美國, 企業佔有率

6. 主要企業概要 - 北美 體外診斷 市場

• 6.1 Abbott Laboratories
• 6.2 Siemens Healthcare
• 6.3 F. Hoffmann-La Roche Ltd.
• 6.4 Beckman Coulter, Inc.
• 6.5 Ortho-Clinical Diagnostics Inc.
• 6.6 bioMerieux S.A.
• 6.7 Becton, Dickinson and Company
• 6.8 Bio-Rad Laboratories, Inc.
• 6.9 Alere Inc.
• 6.10 Sysmex Corporation
• 6.11 Qiagen N.V.
• 6.12 Gen-Probe Incorporated
• 6.13 DiaSorin S.p.A
• 6.14 Thermo Fisher Scientific Inc.
• 6.15 Immucor, Inc.
• 6.16 Hologic, Inc.
• 6.17 Phadia AB
• 6.18 Cepheid
• 6.19 Grifols, S.A.
• 6.20 Life Technologies Corporation
• 6.21 PerkinElmer, Inc.
• 6.22 堀場製作所
• 6.23 Biomedica Diagnostics Inc.
• 6.24 OraSure Technologies, Inc.

7. 體外診斷 市場 開發中產品

• 7.1 臨床化學檢驗 市場 開發中產品
• 7.2 免疫化學檢查 市場 開發中產品
• 7.3 血液檢驗 市場 開發中產品
• 7.4 感染/免疫疾病檢驗 市場 開發中產品
• 7.5 微生物學培養檢驗 市場 開發中產品
• 7.6 組織/細胞檢驗 市場 開發中產品
• 7.7 遺傳基因檢驗 市場 開發中產品

8. 財務交易展望

• 8.1 合併
• 8.2 收購
• 8.3 合作

9. 最新趨勢

• 9.1 策略及產業計畫
• 9.2 產品資訊
• 9.3 法律行為及法規
• 9.4 政府及公益相關

10. 附錄

• 10.1 調查對象的市場定義
• 10.2 調查方法
• 10.3 二級研究
• 10.4 主要研究
• 10.5 資料的模式化
• 10.6 預測
• 10.7 專門委員會
• 10.8 GlobalData 諮詢服務
• 10.9 貨幣換算
• 10.10 諮詢方式
• 10.11 免責聲明

• 表格 1: 體外診斷, 多國間比較, USD 以實額為基礎, 實際成果及預測
• 表格 2: 體外診斷, 北美, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 表格 3: 體外診斷, 北美, 分類間分析, 實際成果及預測
• 表格 4: 體外診斷, 北美, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 表格 5: 體外診斷, 北美, 整體收益 ($m), USD 以實額為基礎，預測
• 表格 6: 體外診斷, 北美, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 7: 體外診斷, 加拿大, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 表格 8: 體外診斷, 加拿大, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 表格 9: 體外診斷, 加拿大, 整體收益 ($m), USD 以實額為基礎，預測
• 表格 10: 臨床化學檢驗, 加拿大, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 11: 遺傳基因檢驗, 加拿大, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 12: 血液檢驗, 加拿大, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 13: 組織/細胞檢驗, 加拿大, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 14: 免疫化學檢查, 加拿大, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 15: 感染/免疫疾病檢驗, 加拿大, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 16: 微生物學培養檢驗, 加拿大, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 17: 體外診斷, 加拿大, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 18: 臨床化學檢驗, 加拿大, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 19: 遺傳基因檢驗, 加拿大, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 20: 血液檢驗, 加拿大, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 21: 組織/細胞檢驗, 加拿大, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 22: 免疫化學檢查, 加拿大, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 23: 感染/免疫疾病檢驗, 加拿大, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 24: 微生物學培養檢驗, 加拿大, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 25: 體外診斷, 美國, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 表格 26: 體外診斷, 美國, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 表格 27: 體外診斷, 美國, 整體收益 ($m), USD 以實額為基礎，預測
• 表格 28: 臨床化學檢驗, 美國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 29: 遺傳基因檢驗, 美國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 30: 血液檢驗, 美國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 31: 組織/細胞檢驗, 美國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 32: 免疫化學檢查, 美國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 33: 感染/免疫疾病檢驗, 美國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 34: 微生物學培養檢驗, 美國, 流通佔有率 各收益 ($m), USD 以實額為基礎
• 表格 35: 體外診斷, 美國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 36: 臨床化學檢驗, 美國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 37: 遺傳基因檢驗, 美國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 38: 血液檢驗, 美國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 39: 組織/細胞檢驗, 美國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 40: 免疫化學檢查, 美國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 41: 感染/免疫疾病檢驗, 美國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 42: 微生物學培養檢驗, 美國, 企業佔有率 各收益 ($m), USD 以實額為基礎
• 表格 43: 臨床化學檢驗 市場 開發中產品
• 表格 44: 免疫化學檢查 市場 開發中產品
• 表格 45: 血液檢驗 市場 開發中產品
• 表格 46: 感染/免疫疾病檢驗 市場 開發中產品
• 表格 47: 微生物學培養檢驗 市場 開發中產品
• 表格 48: 組織/細胞檢驗 市場 開發中產品
• 表格 49: 遺傳基因檢驗 市場 開發中產品
• 表格 50∼173: 體外診斷市場, 北美, 交易內容詳細內容
• 表格 174: 美金V.S.該地貨幣, 北美, 平均匯率

• 圖 1: 體外診斷, 多國間比較, USD 以實額為基礎, 實際成果及預測
• 圖 2: 體外診斷, 北美, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 圖 3: 體外診斷, 北美, 分類間分析, 實際成果及預測
• 圖 4: 體外診斷, 北美, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 圖 5: 體外診斷, 北美, 整體收益 ($m), USD 以實額為基礎，預測
• 圖 6: 體外診斷, 北美, 企業佔有率 (%)
• 圖 7: 體外診斷, 加拿大, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 圖 8: 體外診斷, 加拿大, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 圖 9: 體外診斷, 加拿大, 整體收益 ($m), USD 以實額為基礎，預測
• 圖 10: 體外診斷, 加拿大, 企業佔有率 (%)
• 圖 11: 臨床化學檢驗, 加拿大, 企業佔有率 (%)
• 圖 12: 遺傳基因檢驗, 加拿大, 企業佔有率 (%)
• 圖 13: 血液檢驗, 加拿大, 企業佔有率 (%)
• 圖 14: 組織/細胞檢驗, 加拿大, 企業佔有率 (%)
• 圖 15: 免疫化學檢查, 加拿大, 企業佔有率 (%)
• 圖 16: 感染/免疫疾病檢驗, 加拿大, 企業佔有率 (%)
• 圖 17: 微生物學培養檢驗, 加拿大, 企業佔有率 (%)
• 圖 18: 體外診斷, 美國, 整體收益 ($m), USD 以實額為基礎, 實際成果及預測
• 圖 19: 體外診斷, 美國, 整體收益 ($m), USD 以實額為基礎, 實際成果
• 圖 20: 體外診斷, 美國, 整體收益 ($m), USD 以實額為基礎，預測
• 圖 21: 體外診斷, 美國, 企業佔有率 (%)
• 圖 22: 臨床化學檢驗, 美國, 企業佔有率 (%)
• 圖 23: 遺傳基因檢驗, 美國, 企業佔有率 (%)
• 圖 24: 血液檢驗, 美國, 企業佔有率 (%)
• 圖 25: 組織/細胞檢驗, 美國, 企業佔有率 (%)
• 圖 26: 免疫化學檢查, 美國, 企業佔有率 (%)
• 圖 27: 感染/免疫疾病檢驗, 美國, 企業佔有率 (%)
• 圖 28: 微生物學培養檢驗, 美國, 企業佔有率 (%)
• 圖 29: Abbott Laboratories, 企業佔有率 (%), 北美 體外診斷 市場
• 圖 30: Siemens Healthcare, 企業佔有率 (%), 北美 體外診斷 市場
• 圖 31: F. Hoffmann-La Roche Ltd., 企業佔有率 (%), 北美 體外診斷 市場
• 圖 32: Beckman Coulter, Inc., 企業佔有率 (%), 北美 體外診斷 市場
• 圖 33: Ortho-Clinical Diagnostics Inc., 企業佔有率 (%), 北美 體外診斷 市場
• 圖 34: bioMerieux S．A., 企業佔有率 (%), 北美 體外診斷 市場

目錄

Summary

GlobalData's new report, "North America In Vitro Diagnostics Market Outlook to 2017 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture" provides key market data on the North America In Vitro Diagnostics market - Canada and United States. The report provides value (USD million) data for all the market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

• Countries covered include Canada and United States.
• Market size and company share data for In Vitro Diagnostics market categories - Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
• Annualized market revenues (USD million) data for each of the market categories in each of the country. Data from 2003 to 2010, forecast forward for 7 years to 2017.
• 2010 company shares and distribution shares data for each of the market categories and countries.
• Global corporate-level profiles of key companies operating within the North America In Vitro Diagnostics market..
• Key players covered include Abbott Laboratories, Siemens Healthcare, F. Hoffmann-La Roche Ltd., Beckman Coulter, Inc., Ortho-Clinical Diagnostics Inc., bioMerieux S.A. and others.

Reasons to buy

• Develop business strategies by identifying the key market categories and segments poised for strong growth.
• Develop market-entry and market expansion strategies.
• Design competition strategies by identifying who-stands-where in the North America In Vitro Diagnostics competitive landscape.
• Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
• What are the key distribution channels and what's the most preferred mode of product distribution - Identify, understand and capitalize.

1. Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2. Introduction

• 2.1 What is This Report About?

3. In Vitro Diagnostics in North America

• 3.1 In Vitro Diagnostics Cross Country Comparison, USD Actual, 2003-2017
• 3.2 In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, 2003-2017
• 3.3 In Vitro Diagnostics, North America, Company share (2009-2010)

4. In Vitro Diagnostics In Canada

• 4.1 In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
• 4.2 In Vitro Diagnostics, Canada, Distribution Share (2009-2010)
• 4.3 In Vitro Diagnostics, Canada, Company share (2009-2010)

5. In Vitro Diagnostics In United States

• 5.1 In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017
• 5.2 In Vitro Diagnostics, United States Distribution Share (2009-2010)
• 5.3 In Vitro Diagnostics, United States, Company share (2009-2010)

6. Overview of Key Companies in North America In Vitro Diagnostics Market

• 6.1 Abbott Laboratories
• 6.2 Siemens Healthcare
• 6.3 F. Hoffmann-La Roche Ltd.
• 6.4 Beckman Coulter, Inc.
• 6.5 Ortho-Clinical Diagnostics Inc.
• 6.6 bioMerieux S.A.
• 6.7 Becton, Dickinson and Company
• 6.8 Bio-Rad Laboratories, Inc.
• 6.9 Alere Inc.
• 6.10 Sysmex Corporation
• 6.11 Qiagen N.V.
• 6.12 Gen-Probe Incorporated
• 6.13 DiaSorin S.p.A
• 6.14 Thermo Fisher Scientific Inc.
• 6.15 Immucor, Inc.
• 6.16 Hologic, Inc.
• 6.17 Phadia AB
• 6.18 Cepheid
• 6.19 Grifols, S.A.
• 6.20 Life Technologies Corporation
• 6.21 PerkinElmer, Inc.
• 6.22 HORIBA, Ltd.
• 6.23 Biomedica Diagnostics Inc.
• 6.24 OraSure Technologies, Inc.

7. In Vitro Diagnostics Market Pipeline Products

• 7.1 Clinical Chemisty Market Pipeline Products
• 7.2 Immuno Chemistry Market Pipeline Products
• 7.3 Haematology Market Pipeline Products
• 7.4 Infectious Immunology Market Pipeline Products
• 7.5 Microbiology Culture Market Pipeline Products
• 7.6 Histology and Cytology Market Pipeline Products
• 7.7 Genetic Testing Market Pipeline Products

8. Financial Deals Landscape

• 8.1 Merger
• 8.2 Acquisition
• 8.3 Partnerships

9. Recent Developments

• 9.1 Strategy And Business Planning
• 9.2 Product News
• 9.3 Legal and Regulatory
• 9.4 Government and Public Interest

10. Appendix

• 10.1 Definitions of Markets Covered in the Report
• 10.2 Research Methodology
• 10.3 Secondary Research
• 10.4 Primary Research
• 10.5 Models
• 10.6 Forecasts
• 10.7 Expert Panels
• 10.8 GlobalData Consulting
• 10.9 Currency Conversion
• 10.10 Contact Us
• 10.11 Disclaimer

• Table 1: In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017
• Table 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, 2003-2017
• Table 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2003-2017
• Table 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, Historic, 2003-2010
• Table 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
• Table 6: In Vitro Diagnostics, North America, Company share by Revenue ($m), USD Actual, 2009-2010
• Table 7: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
• Table 8: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010
• Table 9: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
• Table 10: Clinical Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 11: Genetic Testing, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 12: Haematology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 13: Histology And Cytology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 14: Immuno Chemistry, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 15: Infectious Immunology, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 16: Microbiology Culture, Canada, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 17: In Vitro Diagnostics, Canada, Company share by Revenue ($m), USD Actual, 2009-2010
• Table 18: Clinical Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010
• Table 19: Genetic Testing, Canada, Company share by Revenue ($m), USD Actual 2009-2010
• Table 20: Haematology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
• Table 21: Histology And Cytology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
• Table 22: Immuno Chemistry, Canada, Company share by Revenue ($m), USD Actual 2009-2010
• Table 23: Infectious Immunology, Canada, Company share by Revenue ($m), USD Actual 2009-2010
• Table 24: Microbiology Culture, Canada, Company share by Revenue ($m), USD Actual 2009-2010
• Table 25: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017
• Table 26: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Historic, 2003-2010
• Table 27: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
• Table 28: Clinical Chemistry, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 29: Genetic Testing, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 30: Haematology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 31: Histology And Cytology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 32: Immuno Chemistry, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 33: Infectious Immunology, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 34: Microbiology Culture, United States, Distribution Share by Revenue ($m), USD Actual, 2009-2010
• Table 35: In Vitro Diagnostics, United States, Company share by Revenue ($m), USD Actual, 2009-2010
• Table 36: Clinical Chemistry, United States, Company share by Revenue ($m), USD Actual 2009-2010
• Table 37: Genetic Testing, United States, Company share by Revenue ($m), USD Actual 2009-2010
• Table 38: Haematology, United States, Company share by Revenue ($m), USD Actual 2009-2010
• Table 39: Histology And Cytology, United States, Company share by Revenue ($m), USD Actual 2009-2010
• Table 40: Immuno Chemistry, United States, Company share by Revenue ($m), USD Actual 2009-2010
• Table 41: Infectious Immunology, United States, Company share by Revenue ($m), USD Actual 2009-2010
• Table 42: Microbiology Culture, United States, Company share by Revenue ($m), USD Actual 2009-2010
• Table 43: Clinical Chemisty Market Pipeline Products
• Table 44: Immuno Chemistry Market Pipeline Products
• Table 45: Haematology Market Pipeline Products
• Table 46: Infectious Immunology Market Pipeline Products
• Table 47: Microbiology Culture Market Pipeline Products
• Table 48: Histology and Cytology Market Pipeline Products
• Table 49: Genetic Testing Market Pipeline Products
• Table 50: Transonic Systems Merges With Scisense
• Table 51: Vivakor Enters Into Memorandum Of Understanding To Merge With Resolution Biomedical
• Table 52: Pall Corporation To Acquire ForteBio
• Table 53: Shionogi Acquires Remaining 13% Joint Venture Stake In Ezose Sciences
• Table 54: Agilent Technologies Completes Acquisition Of BioSystem Development
• Table 55: Affymetrix To Acquire eBioscience For $330 Million
• Table 56: AMAG Pharmaceuticals Plans For Sale Of The Company
• Table 57: Vermillion Completes Acquisition Of Correlogic Systems For $0.4 Million
• Table 58: Evonik Industries Acquires SurModics Pharmaceuticals From SurModics For $30 Million
• Table 59: Everist Genomics Acquires Angiologix
• Table 60: WuXi PharmaTech Acquires Abgent
• Table 61: OPKO Health Acquires Claros Diagnostics
• Table 62: Miraca Holdings Completes Acquisition Of Caris Diagnostics From Caris Life Sciences For $725 Million
• Table 63: Bio-Rad Laboratories Acquires QuantaLife For $162 Million
• Table 64: Sony Corporation of America Acquires Micronics
• Table 65: PerkinElmer Completes Acquisition Of Caliper Life Sciences For $600 Million
• Table 66: Thermo Fisher Scientific Acquires Intrinsic Bioprobes
• Table 67: EMD Millipore To Acquire Amnis
• Table 68: Modern Mobility Aids Finalizes Acquisition Of LumiGene Technologies
• Table 69: OraSure Technologies Completes Acquisition Of DNA Genotek
• Table 70: Thermo Fisher Scientific Acquires TREK Diagnostic Systems
• Table 71: Solstas Lab Partners Acquires NextWave Diagnostic Laboratories
• Table 72: Solstas Lab Partners Acquires Wilmington Pathology Laboratory
• Table 73: Signal Genetics Acquires DiagnoCure Oncology Laboratories
• Table 74: Luminex Completes Acquisition Of EraGen Biosciences
• Table 75: Solstas Lab Partners Acquires Select Diagnostics
• Table 76: BioMedical Technology Solutions Holdings To Acquire SharpsMD And 2000 Plus Consulting
• Table 77: Nestle Health Science Completes Acquisition Of Prometheus Laboratories
• Table 78: Abcam Acquires MitoSciences
• Table 79: Health Diagnostic Laboratory Acquires Harris Scientific
• Table 80: EKF Diagnostics Completes Acquisition of Stanbio Laboratory
• Table 81: PositiveID Completes Acquisition Of MicroFluidic Systems
• Table 82: Navitar Life Sciences To Acquire Modulation Optics
• Table 83: Myriad Genetics Acquires Rules-Based Medicine
• Table 84: Shrink Nanotechnologies To Acquire Nanopoint
• Table 85: Novelos Therapeutics Acquires Cellectar
• Table 86: LabCorp Completes Acquisition Of Orchid Cellmark For $85 Million
• Table 87: ARAMARK Healthcare Acquires ReMedPar From Berkshire Partners
• Table 88: Quest Diagnostics Completes Acquisition Of Celera
• Table 89: CerMed International Acquires Viridis Bioscience
• Table 90: Bruker BioSciences Completes Acquisition Of Michrom Bioresources
• Table 91: Sparton Acquires Byers Peak
• Table 92: Becton, Dickinson Completes Acquisition Of Accuri Cytometers
• Table 93: Alastair John Gray Sells Stake In Phenomenex To Farajollah Farshad Mahjoor
• Table 94: Trinity Biotech Acquires Phoenix Bio-Tech
• Table 95: VWR International Acquires AMRESCO
• Table 96: Sigma-Aldrich Acquires Resource Technology
• Table 97: Technest Holdings Acquires AccelPath
• Table 98: Endo Pharmaceuticals To Acquire A Pharmaceutical Company
• Table 99: Illumina Acquires Epicentre Biotechnologies
• Table 100: Quest Diagnostics Completes Acquisition Of Athena Diagnostics
• Table 101: HistoRx Enters Into Licensing Agreement With Yale University
• Table 102: BioTime Enters Into Distribution Agreement With USCN Life Science
• Table 103: Critical Path Institute Signs Memorandum Of Understanding With The Hamner Institutes
• Table 104: Tyrian Diagnostics Enters Into Distribution Agreement With NeoClone
• Table 105: Global BioDiagnostics Extends Co-Development Agreement With Foundation for Innovative New Diagnostics
• Table 106: Sony DADC Enters Into Co-Development Agreement With Axela
• Table 107: Lineagen Enters Into Co-Development Agreement With Fast Forward
• Table 108: Pathogenetix Enters Into Co-Development Agreement With Sagentia
• Table 109: Bio-Rad Expands Co-Marketing Agreement With Siemens Medical
• Table 110: Ezose Sciences Enters Into Co-Development Agreement With Merck
• Table 111: Genome British Columbia Enters Into Co-Development Agreement With Genome Canada
• Table 112: Fluxion Biosciences Enters Into Distribution Agreement With EMD Millipore
• Table 113: Roche Enters Into Technology Integration Agreement With Labcyte
• Table 114: Sony DADC BioSciences Enters Into Co-Development Agreement With Maven Biotechnologies
• Table 115: Abbott Laboratories Expands Its Co-Development Agreement With GlaxoSmithKline Biologicals
• Table 116: Olink Bioscience Enters Into Distribution Agreement With Bethyl Laboratories
• Table 117: SuperNova Diagnostics Enters Into Co-Development Agreement With Concile
• Table 118: OncoSec Medical Enters Into Research Agreement With Serametrix
• Table 119: Bruker Enters Into Co-Development Agreement With Lawrence Berkeley National Laboratory
• Table 120: Dako Enters Into Co-Development Agreement With Bristol-Myers
• Table 121: Transgenomic Enters Into Distribution Agreement With ScreenCell
• Table 122: Horizon Discovery Enters Into Co-Development Agreement With Promega
• Table 123: Stemina Biomarker Discovery Enters Into Co-Development Agreement With ILS
• Table 124: Psyche Systems Enters Into Technology Integration Agreement With Aperio Technologies
• Table 125: Life Technologies Enters Into Co-Development Agreement With GlaxoSmithKline Biologicals
• Table 126: PrognosDx Health Entetrs Into Co-Development Agreement With Accium BioSciences
• Table 127: The Molecular Sciences Forms Joint Venture With VTT Technical Research
• Table 128: DxTerity Diagnostics Enters Into Technology Integration Agreement With Caliper Life Sciences
• Table 129: Gold Standard Diagnostics Extends Distribution Agreement With Fujirebio Diagnostics
• Table 130: New England Biolabs Enters Into Co-Marketing Agreement With Rubicon Genomics
• Table 131: WILEX Enters Into Co-Marketing Agreement With ALPCO Diagnostics
• Table 132: Illumina Enters Into Co-Development Agreement With University Of North Texas Health Science Center
• Table 133: Warnex Medical Laboratories Enters Into Distribution Agreement With deCODE genetics
• Table 134: Absorption Systems Enters Into Co-Development Agreement With Temple University And Washington State University
• Table 135: Oasis Diagnostics Enters Into Licensing Agreement With Two Researchers
• Table 136: Bioo Scientific Enters Into Co-Development Agreement With JungWoo
• Table 137: Accelr8 Technology Amends Licensing Agreement With SCHOTT
• Table 138: Warnex PRO-DNA Enters Into Co-Development Agreement With National Research Council of Canada
• Table 139: Orion Genomics Enters Into Licensing Agreement With QIAGEN
• Table 140: Quantum Materials Enters Into Technology Integration Agreement With Nanoaxis
• Table 141: Warnex Enters Into Licensing Agreement With Sorenson Forensics
• Table 142: RedHill Biopharma Enters Into Licensing Agreement With UCF Research Foundation
• Table 143: SuviCa Enters Into Licensing Agreement With University of Colorado
• Table 144: Polymedco Enters Into Distribution Agreement With Cardinal Health
• Table 145: Universal Biosensors Enters Into Co-Development Agreement With Siemens Healthcare Diagnostics
• Table 146: LI-COR Biosciences Enters Into Licensing Agreement With Johns Hopkins University
• Table 147: QIAGEN Enters Into Co-Development Agreement With Eli Lilly
• Table 148: Sun Yat-sen University Enters Into Co-Development Agreement With BioDesign Institute
• Table 149: Lumora Enters Into Licensing Agreement With 3M
• Table 150: NuGEN Technologies Enters Into Co-Development Agreement With Advanced Liquid Logic And Broad Institute
• Table 151: Biocept Enters Into Co-Marketing Agreement With Clarient
• Table 152: Roche Enters Into Distribution Agreement With PerkinElmer
• Table 153: Quanterix Enters Into Co-Development Agreement With STRATEC Biomedical
• Table 154: DNA Diagnostics Center Enters Into Licensing Agreement
• Table 155: Pronexus Enters Into Technology Integration Agreement With RealityCorp
• Table 156: Carl Zeiss Enters Into Licensing Agreement With Prior Scientific
• Table 157: EPIC Enters Into Distribution Agreement With Micro Imaging Technology
• Table 158: BD Diagnostics Enters Into Co-Development Agreement With Lab21
• Table 159: Procognia Enters Into Co-Development Agreement With Caerus Discovery
• Table 160: BioMarCare Technologies Enters Into Co-Development Agreement With Ariadne
• Table 161: Hycor Biomedical Signs Licensing Agreement With Axis-Shield
• Table 162: Thermo Fisher Scientific Enters Into Licensing Agreement With Alere
• Table 163: Quanterix Enters Into Co-Development Agreement With Sony DADC
• Table 164: Canon U.S. Life Sciences Enters Into Co-Development Agreement With The University of Maryland
• Table 165: Mayo Medical Laboratories Enters Into Licensing Agreement With Qiagen
• Table 166: Rhoen-Klinikum Enters Into Co-Development Agreement With Siemens
• Table 167: Proteome Sciences Enters Into Collaboration With Buck Institute
• Table 168: Stratos Product Development Enters Into Co-Development Agreement With Response Biomedical
• Table 169: Gold Standard Diagnostics Enters Into Distribution Agreement With Fujirebio Diagnostics
• Table 170: Roche NimbleGen Enters Into Co-Marketing Agreement With Caliper Life Sciences
• Table 171: Clinical Genomics Extends Its Licensing Agreement With Quest Diagnostics
• Table 172: LaserGen Enters Into Co-Development Agreement With National Instruments
• Table 173: Proteome Sciences Enters Into Co-Development Agreement With H. Lee Moffitt Cancer Center
• Table 174: USD to Local Currency, North America, Average Exchange Rate 2003-2010

• Figure 1: In Vitro Diagnostics, Cross Country Comparison, USD Actual, 2003-2017
• Figure 2: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, 2003-2017
• Figure 3: In Vitro Diagnostics, North America, Cross-Category Analysis, 2003-2017
• Figure 4: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, Historic, 2003-2010
• Figure 5: In Vitro Diagnostics, North America, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
• Figure 6: In Vitro Diagnostics, North America, Company share (%), 2010
• Figure 7: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, 2003-2017
• Figure 8: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Historic, 2003-2010
• Figure 9: In Vitro Diagnostics, Canada, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
• Figure 10: In Vitro Diagnostics, Canada, Company share (%), 2010
• Figure 11: Clinical Chemistry, Canada, Company share (%), 2010
• Figure 12: Genetic Testing, Canada, Company share (%), 2010
• Figure 13: Haematology, Canada, Company share (%), 2010
• Figure 14: Histology And Cytology, Canada, Company share (%), 2010
• Figure 15: Immuno Chemistry, Canada, Company share (%), 2010
• Figure 16: Infectious Immunology, Canada, Company share (%), 2010
• Figure 17: Microbiology Culture, Canada, Company share (%), 2010
• Figure 18: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, 2003-2017
• Figure 19: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Historic, 2003-2010
• Figure 20: In Vitro Diagnostics, United States, Overall Revenue ($m), USD Actual, Forecast, 2010-2017
• Figure 21: In Vitro Diagnostics, United States, Company share (%), 2010
• Figure 22: Clinical Chemistry, United States, Company share (%), 2010
• Figure 23: Genetic Testing, United States, Company share (%), 2010
• Figure 24: Haematology, United States, Company share (%), 2010
• Figure 25: Histology And Cytology, United States, Company share (%), 2010
• Figure 26: Immuno Chemistry, United States, Company share (%), 2010
• Figure 27: Infectious Immunology, United States, Company share (%), 2010
• Figure 28: Microbiology Culture, United States, Company share (%), 2010
• Figure 29: Abbott Laboratories, Company Share (%), North America In Vitro Diagnostics Market, 2010
• Figure 30: Siemens Healthcare, Company Share (%), North America In Vitro Diagnostics Market, 2010
• Figure 31: F. Hoffmann-La Roche Ltd., Company Share (%), North America In Vitro Diagnostics Market, 2010
• Figure 32: Beckman Coulter, Inc., Company Share (%), North America In Vitro Diagnostics Market, 2010
• Figure 33: Ortho-Clinical Diagnostics Inc., Company Share (%), North America In Vitro Diagnostics Market, 2010
• Figure 34: bioMerieux S.A., Company Share (%), North America In Vitro Diagnostics Market, 2010

相關商品

體外診斷設備相關市場調查報告書

全球切片設備市場:開發平台分析，競爭環境，到2018年為止的市場預測
Biopsy Devices - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018
價格 : US $ 3995
出版日期 : 2012年04月

全球分子診斷市場:各國的設施·檢驗數量·銷售額預測
2012 World Molecular Diagnostics Market Overview: Facilities, Test Volumes, and Sales Forecasts by Country
價格 : US $ 1850
出版日期 : 2012年04月

全球微生物測試市場展望：成長機會及業務拓展策略
2012 Microbiology Testing Market Outlook: Growth Opportunities and Strategies
價格 : US $ 28700
出版日期 : 2012年04月

GlobalData發行的醫療設備相關市場調查報告書

全球先進型創傷管理市場:開發平台分析，競爭環境，到2018年為止的市場預測

Advanced Wound Management - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

價格 : US $ 3995

出版日期 : 2012年04月

臨床化學:全球性開發平台分析，競爭情形，到2018年為止的市場未來預測

Clinical Chemistry - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

價格 : US $ 3995

出版日期 : 2012年04月

免疫化學分析儀與檢查套件:全球性開發平台分析，競爭情形，到2018年為止的市場未來預測

Immunochemistry Analyzers and Test Kits - Global Pipeline Analysis, Competitive Landscape and Market Forecasts to 2018

價格 : US $ 3995

出版日期 : 2012年04月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!